EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Literature-based meta-analysis of adverse events accounting for heterogeneous follow-up duration in oncology clinical trials

Sumika Kawaguchi, Satoshi Hattori iD

Research Synthesis Methods · 2026

DOI: 10.1017/rsm.2026.10083 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Research Synthesis Methods, 2026. Verfasst von Sumika Kawaguchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Study Support Center, Wakayama Medical University Hospital, Japan. Hauptthemen laut MEDLINE: Meta-Analysis as Topic, Clinical Trials as Topic, Medical Oncology, Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is difficult to understand the safety profile of drugs based on a single clinical trial since clinical trials are often designed to prove efficacies, and sample size is not powered for safety assessment. Thus, meta-analysis would be a valuable tool to infer the safety profiles utilizing multiple studies. Individual clinical trials usually report the incidence proportions of adverse events (AEs) observed in the study. The follow-up duration may be study-specific, and furthermore different between the treatment groups within a single study. It often occurs in oncology clinical trials and if this is the case, it is hard to interpret the aggregated relative risk of AEs and compare the risk of AEs between the treatment groups with the standard meta-analysis techniques. The progression-free survival or the overall survival is often used as the primary endpoint in oncology clinical trials and the Kaplan–Meier estimates of the survival functions for the primary endpoint are often demonstrated graphically, which give us information of the follow-up duration of the AEs. We propose novel meta-analysis methods for AEs that address differences in follow-up durations by efficiently utilizing the Kaplan–Meier estimates of the primary endpoint. We adapt our approach using both simulated data and real data from a meta-analysis of bevacizumab. Simulation studies demonstrate that the proposed methods perform well when follow-up time differs between trials and groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meta-Analysis as TopicClinical Trials as TopicMedical OncologyNeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansBevacizumabComputer SimulationKaplan-Meier EstimateResearch DesignProgression-Free SurvivalFollow-Up StudiesAntineoplastic AgentsSample SizeAlgorithms

Stichwörter der Autor:innen

Kaplan–Meier estimatorcopulagraph scan softwarerare eventssurvival analysis

Substanzen

BevacizumabAntineoplastic Agents

Autor:innen und Institutionen

  • Clinical Study Support Center, Wakayama Medical University Hospital, Japan.
  • Department of Biomedical Statistics, Graduate School of Medicine and Institute for Open and Transdisciplinary Research Initiatives (OTRI), The University of Osaka, Japan.

ORCID-Profile: Satoshi Hattori

Zitieren

APA

Kawaguchi, S., & Hattori, S. (2026). Literature-based meta-analysis of adverse events accounting for heterogeneous follow-up duration in oncology clinical trials. Research Synthesis Methods. https://doi.org/10.1017/rsm.2026.10083

Vancouver

Kawaguchi S, Hattori S. Literature-based meta-analysis of adverse events accounting for heterogeneous follow-up duration in oncology clinical trials. Research Synthesis Methods. 2026. doi:10.1017/rsm.2026.10083

BibTeX
@article{Kawaguchi2026,
  author = {Kawaguchi, Sumika and Hattori, Satoshi},
  title = {Literature-based meta-analysis of adverse events accounting for heterogeneous follow-up duration in oncology clinical trials},
  journal = {Research Synthesis Methods},
  year = {2026},
  doi = {10.1017/rsm.2026.10083}
}
Kostenlos starten →